Your browser doesn't support javascript.
loading
Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease.
Lenglet, Marion; Robriquet, Florence; Schwarz, Klaus; Camps, Carme; Couturier, Anne; Hoogewijs, David; Buffet, Alexandre; Knight, Samantha J L; Gad, Sophie; Couvé, Sophie; Chesnel, Franck; Pacault, Mathilde; Lindenbaum, Pierre; Job, Sylvie; Dumont, Solenne; Besnard, Thomas; Cornec, Marine; Dreau, Helene; Pentony, Melissa; Kvikstad, Erika; Deveaux, Sophie; Burnichon, Nelly; Ferlicot, Sophie; Vilaine, Mathias; Mazzella, Jean-Michaël; Airaud, Fabrice; Garrec, Céline; Heidet, Laurence; Irtan, Sabine; Mantadakis, Elpis; Bouchireb, Karim; Debatin, Klaus-Michael; Redon, Richard; Bezieau, Stéphane; Bressac-de Paillerets, Brigitte; Teh, Bin Tean; Girodon, François; Randi, Maria-Luigia; Putti, Maria Caterina; Bours, Vincent; Van Wijk, Richard; Göthert, Joachim R; Kattamis, Antonis; Janin, Nicolas; Bento, Celeste; Taylor, Jenny C; Arlot-Bonnemains, Yannick; Richard, Stéphane; Gimenez-Roqueplo, Anne-Paule; Cario, Holger.
Affiliation
  • Lenglet M; École Pratique des Hautes Études, PSL Research University, Paris, France.
  • Robriquet F; Centre de Recherche en Cancérologie et Immunologie Nantes-Angers, INSERM, Université de Nantes and Université d'Angers, Nantes, France.
  • Schwarz K; L'Institut du Thorax, INSERM, Centre National de la Recherche Scientifique (CNRS), Université de Nantes, Nantes, France.
  • Camps C; Centre de Recherche en Cancérologie et Immunologie Nantes-Angers, INSERM, Université de Nantes and Université d'Angers, Nantes, France.
  • Couturier A; L'Institut du Thorax, INSERM, Centre National de la Recherche Scientifique (CNRS), Université de Nantes, Nantes, France.
  • Hoogewijs D; Institute for Transfusion Medicine, University of Ulm, Ulm, Germany.
  • Buffet A; Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Service Baden-Württemberg-Hessen, Ulm, Germany.
  • Knight SJL; Wellcome Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.
  • Gad S; Oxford NIHR Biomedical Research Centre, Oxford, United Kingdom.
  • Couvé S; Institut de Génétique et Développement de Rennes, UMR 6290, CNRS, Université de Rennes, Rennes, France.
  • Chesnel F; Department of Medicine/Physiology, University of Fribourg, Fribourg, Switzerland.
  • Pacault M; Paris Cardiovascular Research Center, INSERM UMR 970, Hôpital Européen Georges Pompidou, Paris, France.
  • Lindenbaum P; Faculté de Médecine, Université Paris Descartes, Paris, France.
  • Job S; Equipe Labellisée, Ligue Nationale Contre le Cancer, Paris, France.
  • Dumont S; Wellcome Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.
  • Besnard T; Oxford NIHR Biomedical Research Centre, Oxford, United Kingdom.
  • Cornec M; École Pratique des Hautes Études, PSL Research University, Paris, France.
  • Dreau H; Institut Gustave Roussy, INSERM UMR 1186, Université Paris-Saclay, Villejuif, France.
  • Pentony M; École Pratique des Hautes Études, PSL Research University, Paris, France.
  • Kvikstad E; Institut Gustave Roussy, INSERM UMR 1186, Université Paris-Saclay, Villejuif, France.
  • Deveaux S; Institut de Génétique et Développement de Rennes, UMR 6290, CNRS, Université de Rennes, Rennes, France.
  • Burnichon N; Centre de Recherche en Cancérologie et Immunologie Nantes-Angers, INSERM, Université de Nantes and Université d'Angers, Nantes, France.
  • Ferlicot S; Service de Génétique Médicale, Centre Hospitalier Universitaire (CHU) de Nantes, Nantes, France.
  • Vilaine M; L'Institut du Thorax, INSERM, Centre National de la Recherche Scientifique (CNRS), Université de Nantes, Nantes, France.
  • Mazzella JM; Programme Cartes d'Identité des Tumeurs, Ligue Nationale Contre le Cancer, Paris, France.
  • Airaud F; Centre de Recherche en Cancérologie et Immunologie Nantes-Angers, INSERM, Université de Nantes and Université d'Angers, Nantes, France.
  • Garrec C; L'Institut du Thorax, INSERM, Centre National de la Recherche Scientifique (CNRS), Université de Nantes, Nantes, France.
  • Heidet L; Service de Génétique Médicale, Centre Hospitalier Universitaire (CHU) de Nantes, Nantes, France.
  • Irtan S; L'Institut du Thorax, INSERM, Centre National de la Recherche Scientifique (CNRS), Université de Nantes, Nantes, France.
  • Mantadakis E; Molecular Diagnostics Laboratories, Molecular Haematology Department, Oxford University Hospitals Trust, Oxford, United Kingdom.
  • Bouchireb K; Wellcome Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.
  • Debatin KM; Oxford NIHR Biomedical Research Centre, Oxford, United Kingdom.
  • Redon R; Wellcome Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.
  • Bezieau S; Oxford NIHR Biomedical Research Centre, Oxford, United Kingdom.
  • Bressac-de Paillerets B; Faculté de Médecine, Université Paris-Sud, Le Kremlin-Bicêtre, France.
  • Teh BT; Predispositions aux Tumeurs du Rein, Réseau Expert National pour Cancers Rares de l'Adulte, PREDIR labellisé par l'Institut National du Cancer (INCa), and.
  • Girodon F; Maladie de VHL et Prédispositions au Cancer du Rein, Réseau d'Oncogénétique, Institut National du Cancer, Le Kremlin-Bicêtre, France.
  • Randi ML; Service d'Urologie, Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris (AP-HP), Le Kremlin-Bicêtre, France.
  • Putti MC; Paris Cardiovascular Research Center, INSERM UMR 970, Hôpital Européen Georges Pompidou, Paris, France.
  • Bours V; Faculté de Médecine, Université Paris Descartes, Paris, France.
  • Van Wijk R; Equipe Labellisée, Ligue Nationale Contre le Cancer, Paris, France.
  • Göthert JR; Predispositions aux Tumeurs du Rein, Réseau Expert National pour Cancers Rares de l'Adulte, PREDIR labellisé par l'Institut National du Cancer (INCa), and.
  • Kattamis A; Maladie de VHL et Prédispositions au Cancer du Rein, Réseau d'Oncogénétique, Institut National du Cancer, Le Kremlin-Bicêtre, France.
  • Janin N; Service de Génétique, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.
  • Bento C; Faculté de Médecine, Université Paris-Sud, Le Kremlin-Bicêtre, France.
  • Taylor JC; Pathology Department, Hôpitaux Universitaires Paris-Sud, AP-HP, Le Kremlin-Bicêtre, France.
  • Arlot-Bonnemains Y; Centre de Recherche en Cancérologie et Immunologie Nantes-Angers, INSERM, Université de Nantes and Université d'Angers, Nantes, France.
  • Richard S; Paris Cardiovascular Research Center, INSERM UMR 970, Hôpital Européen Georges Pompidou, Paris, France.
  • Gimenez-Roqueplo AP; Faculté de Médecine, Université Paris Descartes, Paris, France.
  • Cario H; Equipe Labellisée, Ligue Nationale Contre le Cancer, Paris, France.
Blood ; 132(5): 469-483, 2018 08 02.
Article in En | MEDLINE | ID: mdl-29891534
Chuvash polycythemia is an autosomal recessive form of erythrocytosis associated with a homozygous p.Arg200Trp mutation in the von Hippel-Lindau (VHL) gene. Since this discovery, additional VHL mutations have been identified in patients with congenital erythrocytosis, in a homozygous or compound-heterozygous state. VHL is a major tumor suppressor gene, mutations in which were first described in patients presenting with VHL disease, which is characterized by the development of highly vascularized tumors. Here, we identify a new VHL cryptic exon (termed E1') deep in intron 1 that is naturally expressed in many tissues. More importantly, we identify mutations in E1' in 7 families with erythrocytosis (1 homozygous case and 6 compound-heterozygous cases with a mutation in E1' in addition to a mutation in VHL coding sequences) and in 1 large family with typical VHL disease but without any alteration in the other VHL exons. In this study, we show that the mutations induced a dysregulation of VHL splicing with excessive retention of E1' and were associated with a downregulation of VHL protein expression. In addition, we demonstrate a pathogenic role for synonymous mutations in VHL exon 2 that altered splicing through E2-skipping in 5 families with erythrocytosis or VHL disease. In all the studied cases, the mutations differentially affected splicing, correlating with phenotype severity. This study demonstrates that cryptic exon retention and exon skipping are new VHL alterations and reveals a novel complex splicing regulation of the VHL gene. These findings open new avenues for diagnosis and research regarding the VHL-related hypoxia-signaling pathway.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Polycythemia / RNA Splicing / Exons / Genetic Predisposition to Disease / Von Hippel-Lindau Tumor Suppressor Protein / Von Hippel-Lindau Disease / Mutation Type of study: Diagnostic_studies / Prognostic_studies Limits: Adolescent / Adult / Child / Female / Humans / Male / Middle aged Language: En Journal: Blood Year: 2018 Document type: Article Affiliation country: France Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Polycythemia / RNA Splicing / Exons / Genetic Predisposition to Disease / Von Hippel-Lindau Tumor Suppressor Protein / Von Hippel-Lindau Disease / Mutation Type of study: Diagnostic_studies / Prognostic_studies Limits: Adolescent / Adult / Child / Female / Humans / Male / Middle aged Language: En Journal: Blood Year: 2018 Document type: Article Affiliation country: France Country of publication: United States